Management ChangeJul 8, 2026, 07:02 AM
Aura Biosciences Appoints Jeremy Bender to Board of Directors
AI Summary
Aura Biosciences, Inc. announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Dr. Bender is an accomplished biotechnology leader with extensive experience in late-stage development, commercialization, and value creation in oncology, having most recently led Day One Biopharmaceuticals through its evolution into a commercial-stage company and its subsequent $2.5 billion acquisition. His expertise is expected to strengthen Aura's Board as the company advances its lead candidate, bel-sar, toward potential regulatory approval and prepares for its next phase of growth.
Key Highlights
- Aura Biosciences appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.
- Dr. Bender previously served as CEO of Day One Biopharmaceuticals, leading it to a $2.5 billion acquisition by Servier in 2026.
- He brings deep experience in advancing innovative therapies through late-stage development and commercialization in oncology.
- Aura is advancing bel-sar toward potential regulatory approval for early choroidal melanoma.
- Enrollment is complete in the Phase 3 CoMpass trial for bel-sar.
Price Impact
More from AURA